Pharmacy Pearls: 2023 ADA Standards of Medical Care in Diabetes – Key Updates You Should Know
February 3rd, 2023 | Pharmacy Pearls•DiabetesIn this edition of Pharmacy Pearls, we have compiled some of the key updates from the 2023 American Diabetes Association Standards of Medical Care in Diabetes. One major highlight is that treatment now branches into two pathways: “cardiorenal risk reduction” or “achievement and maintenance of glycemic and weight management goals.” The selection of a pathway should be based on patient-specific goals and comorbidities. Additionally, the guidelines provide a hierarchy for which GLP-1 agonists are more effective for glucose-lowering and weight loss, and SGLT-2 inhibitors are now recommended for patients with HFpEF as well as HFrEF.
Keep in mind that insulin glargine-yfgn, the first interchangeable alternative to Lantus®, remains a cost-savings option for many patients. Please consider prescribing this instead of Lantus® whenever appropriate.
As always, we welcome any questions or feedback you may have. Just email the Pharmacy Team.
Loading...
Reload document 
Open in new tab 
